Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The galactosidase, beta 1-like pseudogene (ENSG00000276391) is annotated as a pseudogene related to the GLB1L family. Pseudogenes are genomic sequences similar to known genes but are generally non-coding and do not produce functional proteins. This particular pseudogene should not be confused with the protein-coding genes *GLB1L* (galactosidase, beta 1-like)[2] or *GLB1* (galactosidase, beta 1), which encode active glycosyl hydrolase enzymes involved in lysosomal function and are implicated in human metabolic disorders. The pseudogene itself does not have a known biological function or involvement in disease, is not a therapeutic target, and is not considered relevant for clinical biomarker or drug development[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Galactosidase, beta 1-like pseudogene.